Usability and Teachability of Continuous Glucose Monitoring Devices in Older Adults and Diabetes Educators: Task Analysis and Ease-of-Use Survey

Psavko, Simon; Katz, N.; Mirchi, Tina; Green, Courtney R.

doi:10.2196/42057

Cited by 4 publications

(3 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, accuracy measurements in the younger cohort (2–6 years old) were relatively few ( 50 ). The G7 CGM system has a lower cognitive burden than earlier CGM systems for older people utilizing it and for trained diabetes care and education specialists ( 51 ).…”

Section: Resultsmentioning

confidence: 99%

Patent analysis of digital sensors for continuous glucose monitoring

Литвинова

Eitenberger

Bilir

et al. 2023

Front. Public Health

View full text Add to dashboard Cite

The high need for optimal diabetes management among an ever-increasing number of patients dictates the development and implementation of new digital sensors for continuous glucose monitoring. The purpose of this work is to systematize the global patenting trends of digital sensors for continuous glucose monitoring and analyze their effectiveness in controlling the treatment of diabetes patients of different ages and risk groups. The Lens database was used to build the patent landscape of sensors for continuous glucose monitoring. Retrospective analysis showed that the patenting of sensors for continuous glucose monitoring had positive trend over the analyzed period (2000–2022). Leading development companies are Dexcom Inc., Abbott Diabetes Care Inc., Medtronic Minimed Inc., Roche Diabetes Care Inc., Roche Diagnostics Operations Inc., Roche Diabetes Care Gmbh, and Ascensia Diabetes Care Holdings Ag, among others. Since 2006, a new approach has emerged where digital sensors are used for continuous glucose monitoring, and smartphones act as receivers for the data. Additionally, telemedicine communication is employed to facilitate this process. This opens up new opportunities for assessing the glycemic profile (glycemic curve information, quantitative assessment of the duration and amplitude of glucose fluctuations, and so on), which may contribute to improved diabetes management. A number of digital sensors for minimally invasive glucose monitoring are patented, have received FDA approval, and have been on the market for over 10 years. Their effectiveness in the clinic has been proven, and advantages and disadvantages have been clarified. Digital sensors offer a non-invasive option for monitoring blood glucose levels, providing an alternative to traditional invasive methods. This is particularly useful for patients with diabetes who require frequent monitoring, including before and after meals, during and after exercise, and in other scenarios where glucose levels can fluctuate. However, non-invasive glucose measurements can also benefit patients without diabetes, such as those following a dietary treatment plan, pregnant women, and individuals during fasting periods like Ramadan. The availability of non-invasive monitoring is especially valuable for patients in high-risk groups and across different age ranges. New world trends have been identified in the patenting of digital sensors for non-invasive glucose monitoring in interstitial skin fluid, saliva, sweat, tear fluid, and exhaled air. A number of non-invasive devices have received the CE mark approval, which confirms that the items meet European health, safety, and environmental protection standards (TensorTip Combo-Glucometer, Cnoga Medical Ltd.; SugarBEAT, Nemaura Medical; GlucoTrack, GlucoTrack Inc.), but are not FDA-approved yet. The above-mentioned sensors have characteristics that make them popular in the treatment of diabetes: they do not require implantation, do not cause an organism reaction to a foreign body, and are convenient to use. In the EU, in order to increase clinical safety and the level of transparency about medical devices, manufacturers must obtain certificates in accordance with Regulation (EU) 2017/745, taking into account the transition period. The development of systems, which include digital sensors for continuous glucose monitoring, mobile applications, and web platforms for professional analysis of glycemic control and implementation of unified glycemic assessment principles in mobile healthcare, represent promising approaches for controlling glycaemia in patients.

show abstract

Section: Resultsmentioning

confidence: 99%

Patent analysis of digital sensors for continuous glucose monitoring

Литвинова

Eitenberger

Bilir

et al. 2023

Front. Public Health

View full text Add to dashboard Cite

show abstract

“…Utilization of any glycemic device can include challenges regarding manual dexterity in older adults who may have physical limitations with inability to place CGM devices without assistance. One study by Psavko et al 31 assessed the ease of use of CGM in older adults and noted reduced cognitive burden and improved usability with subsequent advancements and reduced number of tasks required to place a CGM with a new generation of devices studied. In addition, utilizing a personal smartphone as a receiver for CGM may be a barrier for patients who are not familiar with this technology.…”

Section: Adoption Of Cgm and Barriers In Older Adultsmentioning

confidence: 99%

Continuous Glucose Monitoring in Older Adults: What We Know and What We Have Yet to Learn

Price,

Callahan,

Aloi

et al. 2024

J Diabetes Sci Technol

View full text Add to dashboard Cite

Objective: To assess the growing use of continuous glucose monitoring (CGM) systems by older adults and explore additional areas integration that could benefit adults with frailty. Background: The use of CGM devices has expanded rapidly in the last decade. This has been supported by substantial data showing significant benefit in glycemic metrics: hemoglobin A1c improvements, less hypoglycemia, and improved quality of life. However, sub-populations, such as older persons, exist where available data are limited. Furthermore, frail older adults represent a heterogeneous population with their own unique challenges to the management of diabetes. This group has some of the poorest outcomes related to the sequela of diabetes. For example, hypoglycemia resulting in significant morbidity and mortality is more frequent in older person with diabetes than in younger persons with diabetes. Method: We present a concise literature review on CGM use in the older adult as well as expand upon glycemic and non-glycemic benefits of CGM for patients, caregivers, and providers. Retrospective analysis of inpatient glycemic data of 16,935 older adults with Type 2 diabetes mellitus at Atrium Health Wake Forest Baptist indicated those with fraility managed with insulin or sulfonylurea had the highest rates of delirium (4.8%), hypoglycemia (3.5%), cardiovascular complications (20.2%) and ED visits/hospitalizatoins (49%). In addition, we address special consideration of specific situations including inpatient, palliative and long term care settings. Conclusion: This review article summarizes the available data for CGM use in older adults, discusses the benefits and obstacles with CGM use in this population, and identifies areas of future research needed for improved delivery of care to older persons with diabetes.

show abstract

“…A seventh-generation “G7” CGM system (Dexcom) provides several improvements over the G6 system, including better accuracy in nonpregnant adults, 20 a simpler insertion process, 21 a shorter warmup period, and a smaller thinner wearable. 22 The Dexcom G7 has received FDA clearance in the United States, where it is indicated for the management of diabetes in persons 2 years and older and can be worn during pregnancy for all types of diabetes.…”

Section: Introductionmentioning

confidence: 99%

Performance of the Dexcom G7 Continuous Glucose Monitoring System in Pregnant Women with Diabetes

Polsky,

Valent,

Isganaitis

et al. 2024

Diabetes Technology & Therapeutics

View full text Add to dashboard Cite

Background: We evaluated accuracy and safety of a seventh-generation real-time continuous glucose monitoring (CGM) system during pregnancy. Materials and Methods: Evaluable data for accuracy analysis were obtained from 96 G7 sensors (Dexcom, Inc.) worn by 96 of 105 enrolled pregnant women with type 1 ( n = 59), type 2 ( n = 21), or gestational diabetes ( n = 25). CGM values were compared with arterialized venous glucose values from the YSI comparator instrument during 6-h clinic sessions at different time points throughout the sensors' 10-day wear period. The primary endpoint was the proportion of CGM values in the 70–180 mg/dL range within 15% of comparator glucose values. Secondary endpoints included the proportion of CGM values within 20% or 20 mg/dL of comparator values ≥ or <100 mg/dL, respectively (the %20/20 agreement rate). Results: Of the 1739 pairs with CGM in the 70–180 mg/dL range, 83.2% were within 15% of comparator values. The lower bound of the 95% confidence interval was 79.8%. Of the 2102 pairs with CGM values in the 40–400 mg/dL range, the %20/20 agreement rate was 92.5%. Of the 1659 pairs with comparator values in the 63–140 mg/dL range, the %20/20 agreement rate was 92.3%. The %20/20 agreement rates on days 1, 4 and 7, and 10 were 78.6%, 96.3%, and 97.3%, respectively. Consensus error grid analysis showed 99.8% of pairs in the clinically acceptable A and B zones. There were no serious adverse events. The sensors' 10-day survival rate was 90.3%. Conclusion: The G7 system is accurate and safe during pregnancies complicated by diabetes and does not require confirmatory fingerstick testing. Clinical Trial Registration: NCT04905628

show abstract

Usability and Teachability of Continuous Glucose Monitoring Devices in Older Adults and Diabetes Educators: Task Analysis and Ease-of-Use Survey

Cited by 4 publications

References 29 publications

Patent analysis of digital sensors for continuous glucose monitoring

Patent analysis of digital sensors for continuous glucose monitoring

Continuous Glucose Monitoring in Older Adults: What We Know and What We Have Yet to Learn

Performance of the Dexcom G7 Continuous Glucose Monitoring System in Pregnant Women with Diabetes

Contact Info

Product

Resources

About